#USA #Boston #Cancer Treatment #Ratio Therapeutics #Kenan Turnacioglu

Ratio Therapeutics Welcomes Kenan Turnacioglu to Its Board of Directors

On September 17, 2026, Ratio Therapeutics Inc., a clinical-stage pharmaceutical company known for its innovative approach in the development of radiopharmaceuticals for cancer treatments, announced an important addition to its leadership team: Dr. Kenan Turnacioglu. With over twenty years of extensive experience in healthcare investment, biotechnology, and corporate governance, Dr. Turnacioglu is expected to provide invaluable insights to the company's strategic direction.

A Valuable Asset for Innovation

Dr. Turnacioglu is recognized for his unique combination of scientific rigor and practical insight into the biotechnology landscape, especially regarding oncology. As the Chairman and CEO of Ratio, Dr. Jack Hoppin expressed enthusiasm over the appointment, emphasizing Kenan's comprehensive expertise in life sciences and healthcare investing.

"Kenan brings a rare combination of scientific depth, long-term healthcare-investing experience, and firsthand perspective helping build and govern innovative life sciences companies," said Dr. Hoppin. This sentiment underscores the importance Ratio places on having a knowledgeable board that can guide its innovative pursuits in radiopharmaceutical development.

Addressing Practical Challenges

Dr. Turnacioglu shared his excitement about Ratio's mission, particularly regarding its commitment to address practical challenges in the radiopharmaceutical sector. His focus lies on optimizing drug delivery, enhancing tumor uptake, and ensuring manufacturability—elements crucial for advancing the efficacy of cancer treatments.

"Ratio has assembled an experienced team and differentiated technology platforms," Dr. Turnacioglu highlighted, asserting the company's position at a transformative juncture within the radiopharmaceutical industry.

Notable Background

Dr. Turnacioglu has previously held significant roles in various health-related companies, including Immunai, Massive Bio, and Sentonix. His background includes being a General Partner at Catalio Capital Management and co-founding PointState Capital Management, where he oversaw healthcare and consumer portfolios. His long-standing career includes serving on boards for organizations such as Paige AI and NYU Langone Cancer Center, evidencing his commitment to advancing healthcare.

Dr. Turnacioglu earned his B.A. from Rutgers University and attained his Ph.D. from the University of Pennsylvania, with postdoctoral training at Johns Hopkins University, showcasing his strong academic foundation in life sciences.

About Ratio Therapeutics

With its headquarters located in Boston, Ratio Therapeutics is at the forefront of developing next-generation radiopharmaceuticals targeting solid tumors. Their commitment to innovation is reflected in their proprietary RD platforms: Trillium™ and Macropa™, which are designed to create specialized radiopharmaceuticals for therapeutic and imaging purposes.

The company is determined to ensure high-quality production through a hybrid manufacturing approach utilizing both contract development and manufacturing organizations (CDMOs) and its state-of-the-art facility located in Salt Lake City, Utah. This strategy not only ensures reliability in supply but also enhances the quality of radiopharmaceuticals produced.

For more insights on Ratio Therapeutics and its advanced pipeline, please visit www.ratiotx.com and follow them on social media platforms like Twitter (X) and LinkedIn.